美国面向消费者的营销网站中提供眼科疾病「细胞治疗」的诊所评估
本研究通过关键词互联网搜索与网站内容分析,横断面调查截至2017年9月16日美国直接面向消费者营销、并宣传用「细胞治疗」治疗眼科疾病的公司。因缺乏这些治疗的数据,作者主张对医生和患者提示谨慎。
要点
- 40家公司、76家诊所通过网站直接面向消费者营销眼科「细胞治疗」。
- 细胞来源以自体脂肪来源干细胞(35家)和自体骨髓来源干细胞(8家)为主。
- 最常宣传的适应证为黄斑变性(35家)、视神经炎(18家)、视网膜色素变性(17家)、糖尿病视网膜病变(16家)。
核心结论
- 眼科「细胞治疗」在美国通过直接面向消费者营销策略 readily available。
- 这些诊所从多种来源采集「细胞」,以不同方法用于多种眼科疾病。
- 因这些治疗数据有限,有必要向医生和患者提倡对商业「细胞治疗」诊所提供的治疗保持谨慎。
研究设计与样本
- 横断面研究。
- 纳入美国境内、参与直接面向消费者在线营销、网站可进行内容分析、并宣传治疗眼科疾病的企业。
- 采用系统、广泛的关键词互联网搜索,对企业网站进行内容分析,识别、记录并分析截至2017年9月16日营销眼科「细胞治疗」的美国企业。
主要发现
- 40家公司、76家诊所使用「细胞治疗」治疗眼科疾病。
- 诊所数量最多的州为加利福尼亚(23)、佛罗里达(12)、伊利诺伊(10)。
- 40家公司均说明了细胞来源:自体脂肪来源干细胞35家(67%)、自体骨髓来源干细胞8家(15%)、羊膜干细胞2家(4%)、外周血来源干细胞2家(4%)、脐带血干细胞2家(4%)、异体骨髓来源干细胞1家(2%)、胎盘干细胞1家(2%)、异种细胞1家(2%)。
- 最常宣传的眼科疾病包括黄斑变性(35)、视神经炎(18)、视网膜色素变性(17)、糖尿病视网膜病变(16)。
临床怎么用
- 眼科医生面对患者询问商业「细胞治疗」时,应告知这些治疗数据有限并提倡谨慎。
- 患者可能通过直接面向消费者网站接触眼科「细胞治疗」,需识别其细胞来源与给药途径的多样性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: "Cell therapy" is becoming increasingly available to the public via online direct-to-consumer advertisement within the United States (U.S.). The current study investigates the scope of "cell therapy" clinics across the U.S. that advertise and offer "cell therapy" for ocular conditions based on information provided on their websites. DESIGN: Cross-sectional study. PARTICIPANTS: The study included companies that are U.S.-based, participate in direct-to-consumer online marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. METHODS: Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses marketing "cell therapy" for ocular conditions as of September 16, 2017. MAIN OUTCOME MEASURES: Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. RESULTS: Forty companies with 76 clinics use "cell therapy" to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67%), autologous bone marrow-derived stem cells (8; 15%), amniotic stem cells (2; 4%), peripheral blood-derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone marrow-derived stem cells (1; 2%), placental stem cells (1; 2%), and xenocells (1; 2%). The most commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16). The most common routes of administration were intravenous (22) and "unspecified" (12); however, other companies listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2), eye injections (2), retrofundal injection (1), sub-Tenon injection (1), intraocular injection with vitrectomy (1), and eye drops (1). The cost of advertised "cell therapy" ranged from $4000 to $10 500. CONCLUSIONS: "Cell therapy" for ocular conditions is readily available via direct-to-consumer marketing strategies across the United States. The "cells" are harvested from numerous sources and administered through different methods for multiple ocular conditions at these "cell therapy" clinics. Limited data for these treatments necessitates advocating caution to physicians and patients about treatments offered at commercial "cell therapy" clinics.
引用
- Nirwan RS, Albini TA, Sridhar J, et al. Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States. Ophthalmology. 2019. PMID: 30904542. doi:10.1016/j.ophtha.2019.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。